Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
Sponsor: Silesian Centre for Heart Diseases
Summary
Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.
Official title: The Effect of Pancreatin Added to Standard Antihyperglycemic Therapy on Metabolic Control in Patients With Type 2 Diabetes
Key Details
Gender
All
Age Range
35 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-08-01
Completion Date
2027-12-31
Last Updated
2026-10-01
Healthy Volunteers
No
Conditions
Interventions
Pancreatin
Pancreatin 25 000 U with each of the 3 main meals daily for 3 months
Placebo
Placebo capsule with each of the 3 main meals daily for 3 months
Locations (1)
Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze
Zabrze, Silesian Voivodeship, Poland